Becton Dickinson & Co(us:BDX)
226.04
-1.32%
Updated on 2025-04-02
Open:228.75
Close:226.04
High:229.00
Low:225.54
Prev Close:229.06
Volume:1.71M
Turnover:387.93M
Turnover Ratio:0.60%
Shares:287.14M
MarketCap:64.90B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1625 | 252804150 | 87.46% | 98 | 599 | 677 |
| 2024-03-31 | 1634 | 243041019 | 84.09% | 136 | 568 | 698 |
| 2023-12-31 | 1645 | 250517720 | 86.71% | 164 | 485 | 762 |
| 2023-09-30 | 1603 | 252157110 | 86.83% | 104 | 518 | 680 |
| 2023-06-30 | 1600 | 250311080 | 86.28% | 131 | 536 | 653 |
| 2023-03-31 | 1567 | 246879122 | 86.92% | 105 | 520 | 665 |
| 2022-12-31 | 1583 | 246491689 | 86.82% | 149 | 517 | 658 |
| 2022-09-30 | 1536 | 246791046 | 87.09% | 69 | 525 | 659 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Vanguard Group Inc | 26308043 | 9.10% | 123277 | 0.47% |
| 2024-06-30 | Blackrock Inc. | 22260900 | 7.70% | -548296 | -2.40% |
| 2024-06-30 | State Street Corp | 13846500 | 4.79% | 315507 | 2.33% |
| 2024-06-30 | Morgan Stanley | 11330104 | 3.92% | 617180 | 5.76% |
| 2024-06-30 | Price T Rowe Associates Inc /Md/ | 10744182 | 3.72% | 623855 | 6.16% |
| 2024-06-30 | T. Rowe Price Investment Management, Inc. | 7755251 | 2.68% | 250274 | 3.33% |
| 2024-06-30 | Geode Capital Management, Llc | 6174412 | 2.14% | 143446 | 2.38% |
| 2024-06-30 | Generation Investment Management Llp | 5407473 | 1.87% | 2207127 | 68.97% |
| 2024-06-30 | Ameriprise Financial Inc | 5055354 | 1.75% | 302893 | 6.37% |
| 2024-06-30 | Massachusetts Financial Services Co /Ma/ | 4905114 | 1.70% | 87230 | 1.81% |
About
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Address:1 Becton Drive
Website:http://www.bd.com
Market Movers